DR. RUPAL SATISH BHATT, M.D.
Osteopathic Medicine at Brookline Ave, Boston, MA
License number
Massachusetts 214113
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
330 Brookline Ave, Boston, MA 02215
Phone
(617) 667-5288
Professional information
Dr. Rupal S Bhatt, Boston MA - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
Beth Israel Deacnss Medical Center ONC
330 Brookline Ave, Boston 02215
(617) 667-1921 (Phone)
330 Brookline Ave, Boston 02215
(617) 667-1921 (Phone)
Certifications:
Internal Medicine, 2003, Medical Oncology, 2007
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Beth Israel Deacnss Medical Center ONC
330 Brookline Ave, Boston 02215
Beth Israel Deaconess Medical Center
330 Brookline Ave, Boston 02215
330 Brookline Ave, Boston 02215
Beth Israel Deaconess Medical Center
330 Brookline Ave, Boston 02215
Education:
Medical School
Joan Sanford I Weill Medical College Of Cornell University
Graduated: 2000
Beth Israel Deaconess Med Center
Joan Sanford I Weill Medical College Of Cornell University
Graduated: 2000
Beth Israel Deaconess Med Center
Alk1 Antagonists And Their Uses In Treating Renal Cell Carcinoma
US Patent:
2013020, Aug 8, 2013
Filed:
Feb 1, 2013
Appl. No.:
13/757672
Inventors:
Rupal S. BHATT - Roslindale MA, US
Ravindra Kumar - Acton MA, US
James W. Mier - Brookline MA, US
Robert Pearsall - Woburn MA, US
Matthew Sherman - Newton MA, US
Nicolas Solban - Brighton MA, US
Ravindra Kumar - Acton MA, US
James W. Mier - Brookline MA, US
Robert Pearsall - Woburn MA, US
Matthew Sherman - Newton MA, US
Nicolas Solban - Brighton MA, US
International Classification:
A61K 38/45, A61K 31/404, A61K 31/44, A61K 31/436, A61K 31/4439, A61K 31/4709, A61K 31/517, A61K 39/395, A61K 31/506
US Classification:
4241341, 424 945, 4241391
Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo.